U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06909825) titled 'FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)' on March 21.
Brief Summary: This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.
Study Start Date: Feb. 26
Study Type: INTERVENTIONAL
Condition:
Metastat...